Gilead Sciences Inc
NASDAQ: GILD
$89.76
-$0.43 (-0.5%)
Real Time Data Delayed 15 Min.
GILD Articles
24/7 Wall St. has reviewed the short interest in the top biotech companies, without focusing on speculative companies.
Published:
Gilead Sciences was picked up by Anthem to provide its hepatitis C drug as the primary option for patients.
Published:
ThinkstockLooking back at 2014, biotechs had a phenomenal year, and this looks to continue into 2015. The NYSE Arca Biotech index was up over 45% for 2014, and Wells Fargo expects that the biotech...
Published:
Last Updated:
A new research report from the analysts at Cowen highlights the firm's top health care picks, many of which have some huge upside potential to the posted price targets.
Published:
Tuesday's top analyst upgrades, downgrades and initiations seen from Wall Street research calls include GE, Gilead Sciences, Oracle, Under Armour and El Pollo Loco.
Published:
Is it possible that Gilead Sciences is already coming back into favor after just a week of being in the doghouse?
Published:
Monday's top analyst upgrades, downgrades and initiations include Ambarella, Gilead Sciences, MarkWest Energy Partners, PNC Financial Services, Skyworks Solutions, RigNet and Sonus Networks.
Published:
Analysts are beginning to make their calls for what the future will hold for Gilead Sciences, AbbVie and Express Scripts.
Published:
AbbVie and Express Scripts have entered into an exclusive agreement under which Express Scripts will distribute AbbVie's hepatitis treatment.
Published:
The short interest data are out for the November 28 settlement date, and 24/7 Wall St. has reviewed the top biotech companies.
Published:
Tuesday's top analyst upgrades and downgrades from 24/7 Wall St. include Cisco Systems, Dreamworks Animation, Lululemon Athletica, Schlumberger and Verizon Communications.
Published:
ThinkstockThe short interest data are out for the November 14 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or...
Published:
Last Updated:
24/7 Wall St. has identified five of the lowest performing health care stocks over the past month which need to catch up to peers.
Published:
With the markets at or near record highs, the volume of insider selling has reached some of the highest levels this year.
Published:
A new research report from the analysts at UBS focuses on four companies that stand to benefit from rising demand for the drugs they produce that treat hepatitis C.
Published: